In the wake of the increase in Current Liabilities in the third quarter 2026, Quick Ratio fell to 0.46 a new company low.

Within Major Pharmaceutical Preparations industry 395 other companies have achieved higher Quick Ratio than Royalty Pharma Plc in third quarter 2026. While Quick Ratio total ranking has improved so far during the Q3 2026 to 1901, from total ranking in the second quarter 2026 at 2491.

Explain Quick Ratio?
How much Cash & cash equivalents RPRX�s has?
What are RPRX�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/RPRX/financial-strength

https://api.csimarket.com/api/v1/companies/RPRX/fundamentals

https://api.csimarket.com/api/v1/companies/RPRX/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

RPRX Quick Ratio	(Sep 30 2026) Q3	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3
Y / Y Current Liabilities Change	122.12 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	-42.95 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	0.46	Subscribe	Subscribe	Subscribe	Subscribe
RPRX's Total Ranking	# 1901	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	86.87 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	-34.9 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio third quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 396
Healthcare Sector	# 749
Overall Market	# 2708

Quick Ratio Statistics
High	Average	Low
35.91	8.73	0.46
(Sep 30 2023)		(Sep 30 2026)

Financial Statements
Royalty Pharma Plc's Current Liabilities	$ 1,179 Millions	Visit RPRX's Balance sheet
Royalty Pharma Plc's Cash & cash equivalent	$ 545 Millions	Visit RPRX's Balance sheet
Source of RPRX's Sales		Visit RPRX's Sales by Geography

Cumulative Royalty Pharma Plc's Quick Ratio

RPRX's Quick Ratio for the trailling 12 Months

RPRX Quick Ratio	(Sep 30 2026) 12 Months	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	-25.39 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	-37.62 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	0.88	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 3913	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	27.78 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	-13.5 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to RPRX Financial Strength Comparisons >> Go to Compare RPRX Quick Ratio to its Competitors

On the trailing twelve months basis Due to jump in Current Liabilities in the Q3 2026 to $1,179.00 millions, cumulative Quick Ratio decreased to 0.88 below the Royalty Pharma Plc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 433 other companies have achieved higher Quick Ratio than Royalty Pharma Plc. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 3145 to 3913.

Explain Quick Ratio?
How much Cash & cash equivalents RPRX�s has?
What are RPRX�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 434
Healthcare Sector	# 888
Within the Market	# 3913

trailing twelve months Quick Ratio Statistics
High	Average	Low
21.45	7.17	0.75
(Mar 31 2014)		(Jun 30 2025)

Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Sep 30 2026 MRQ Cash & cash equivalent	Sep 30 2026 MRQ Current Liabilities
Vertex Pharmaceuticals Inc	1.26	$ 6,303.300 Millions	$ 5,000.300 Millions
Nature s Sunshine Products inc	1.22	$ 89.377 Millions	$ 73.488 Millions
Ovid Therapeutics Inc	1.16	$ 13.811 Millions	$ 11.858 Millions
Filana Therapeutics Inc	1.12	$ 46.990 Millions	$ 41.946 Millions
Phathom Pharmaceuticals Inc	1.06	$ 184.558 Millions	$ 174.902 Millions
Eton Pharmaceuticals Inc	1.03	$ 55.628 Millions	$ 54.095 Millions
Akebia Therapeutics Inc	0.98	$ 159.254 Millions	$ 162.349 Millions
Acadia Pharmaceuticals Inc	0.97	$ 322.365 Millions	$ 332.217 Millions
Alkermes Plc	0.97	$ 631.314 Millions	$ 651.933 Millions
Geron Corporation	0.94	$ 69.794 Millions	$ 74.248 Millions
Mirum Pharmaceuticals Inc	0.86	$ 243.188 Millions	$ 283.080 Millions
Amphastar Pharmaceuticals Inc	0.86	$ 262.786 Millions	$ 306.303 Millions
Aclaris Therapeutics Inc	0.84	$ 20.394 Millions	$ 24.222 Millions
Seres Therapeutics Inc	0.84	$ 17.528 Millions	$ 20.893 Millions
Jazz Pharmaceuticals Plc	0.80	$ 2,036.400 Millions	$ 2,540.300 Millions
Zomedica Corp	0.80	$ 7.281 Millions	$ 9.096 Millions
Pfizer Inc	0.79	$ 25,140.000 Millions	$ 31,726.000 Millions
Xencor Inc	0.78	$ 59.622 Millions	$ 76.266 Millions
Janux Therapeutics Inc	0.77	$ 41.818 Millions	$ 54.247 Millions
Arcus Biosciences Inc	0.76	$ 151.000 Millions	$ 199.000 Millions
Ligand Pharmaceuticals Incorporated	0.75	$ 374.303 Millions	$ 500.569 Millions
Ionis Pharmaceuticals Inc	0.68	$ 296.303 Millions	$ 435.292 Millions
Liquidia Corporation	0.68	$ 396.091 Millions	$ 585.397 Millions
Bristol myers Squibb Company	0.67	$ 12,581.000 Millions	$ 18,753.000 Millions
Harrow Inc	0.66	$ 75.336 Millions	$ 114.224 Millions
Supernus Pharmaceuticals inc	0.62	$ 176.171 Millions	$ 285.397 Millions
Axsome Therapeutics Inc	0.62	$ 313.859 Millions	$ 509.719 Millions
Travere Therapeutics Inc	0.59	$ 123.542 Millions	$ 210.912 Millions
Clene Inc	0.58	$ 9.887 Millions	$ 17.114 Millions
Zoetis Inc	0.57	$ 1,533.000 Millions	$ 2,682.000 Millions

Date modified: 2026-11-06T13:04:08+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.